The CATCH+ Revascularization Device is designed for use in the fl ow restoration of patients with ischemic stroke due to large intracranial vessel occlusion. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. The CATCH+ Revascularization Device should only be used by physicians trained in interventional neuroradiology and treatment of ischemic stroke. CATCH+ is manufactured by BALT EXTRUSION 10, rue de la Croix Vigneron, 95 160 Montmorency.
Introduction
Endovascular treatment options for cerebral vasospasm include chemical injections of spasmolytics and balloon angioplasty. [1] [2] [3] [4] Balloon angioplasty is commonly performed for the middle cerebral artery (MCA) with relative ease and good outcomes. [5] [6] [7] [8] [9] [10] However, angioplasty of the anterior cerebral artery (ACA) is perceived to be a challenging endeavor and is not routinely performed due to technical and safety concerns. 2, [11] [12] [13] Unlike the MCA, the ACA is a much smaller vessel with sharp angles to navigate, particularly when traversing the anterior communicating artery (ACoA). Given this anatomical hurdle of catheterizing the ACA segments, balloon angioplasty of the ACA is frequently overlooked as a therapeutic option. In an attempt to demonstrate the feasibility and safety of balloon angioplasty of the ACA, we present one of the largest published series of patients who successfully underwent balloon angioplasty of various ACA segments for the treatment of vasospasm after aneurysmal subarachnoid hemorrhage (SAH).
Methods

Patient selection
After Institutional Review Board approval, patients who underwent vasospasm treatment following SAH at our institution between 2011 and 2016 were retrospectively reviewed. All patients were monitored in the neurosurgical intensive care unit and placed on nimodipine and seizure prophylaxis. Vasospasm surveillance consisted of hourly neurological exams and daily transcranial Doppler ultrasound (TCD). All patients (n ¼ 17) who underwent balloon angioplasty for treatment of vasospasm involving the ACA were identified and included.
Pre-procedural neurological
Department of Neurosurgery, University of Illinois at Chicago, USA examinations were compared to the best postprocedural examination within 24 hours of the procedure. Clear neurological improvement was defined as improved cognition, motor strength, or speech from the pre-procedural exam, and was determined only in examinable patients. Our institution's neurosurgical residents performed all neurological examinations in the presence of the senior author (AA).
Indications for balloon angioplasty
Patients found to have a change in clinical examination from baseline, including altered cognition, pronator drift, motor weakness, or change in the speech, and stable computed tomography head scans underwent digital subtraction angiography (DSA) with the intention to treat soon after symptoms occurred. During DSA, patients identified to have vasospasm were treated based on the degree of angiographic spasm (mild < 25%, moderate 25-50%, or severe >50%). For mild vasospasm of the ACA, MCA, and supraclinoid internal carotid artery (ICA), symptomatic patients were treated with verapamil infusion in the respective ICA. Balloon angioplasty was performed only in those patients with moderate or severe vasospasm refractory to at least one trial of verapamil infusion through the respective ICA. ACA balloon angioplasty was performed for the following indications: (1) severe, symptomatic vasospasm that did not improve with verapamil during the same session; or (2) moderate, recurrent symptomatic vasospasm that was treated with verapamil in a previous session.
ACA balloon angioplasty technique
All patients were brought to our biplane neuro-angiography suite (Artis zee, Siemens Healthineers, Erlangen, Germany). DSA images were routinely saved to PACS, and the entire unedited DSA was archived on a separate DVD in DICOM format. All procedures were performed under general anesthesia and with systemic heparinization. A trans-femoral approach was used in all cases. Upon visualization of vasospasm, at least 20 mg of verapamil was infused into the corresponding ICA over 15-30 minutes. When check angiography post verapamil did not show significant improvement in vessel caliber, the decision was made to balloon angioplasty according to the indications described above. ACA balloon angioplasty was performed with a HyperForm 3 mm Â 7 mm balloon (Covidien Ltd., Dublin, Ireland) over an X-Pedion 0.010 microwire (Covidien Ltd.) or Asahi Chikai 0.010 microwire (Asahi Intecc, Aichi, Japan). Verapamil was also infused via the guide catheter during balloon angioplasty.
Our technique consists of balloon inflation in a stepwise graded fashion along the entire length of the vessel. We start at the proximal end of the vessel and travel distally in a steady manner. Upon treatment at the distal end of the involved vessel, we reverse direction and continue to inflate the balloon intermittently from distal to proximal. Thus, each spasm segment of the vessel is treated twice. We inflate the balloon just enough to provide a moderate angioplasty (50% balloon inflation) of the vessel. Depending on the patient's anatomy and degree of spasm of the ipsilateral ACA segment, we occasionally use the anterior communicating artery to cross to the contralateral side to treat distal ACA segments as needed. Our technique is demonstrated in Supplementary Video 1 and illustrated in 
Vessel caliber measurements
All ACA angioplasty segments were analyzed for preand post-angioplasty measurements. Degree of stenosis from vasospasm was recorded as mild (<25%), moderate (25-50%), or severe (>50%). Percent stenosis was calculated using the following equation:
[(width of proximal non-stenotic segment-width of maximal stenotic segment)/width of proximal non-stenotic segment] Â 100%
Results
Patient characteristics
Seventeen patients underwent ACA segment angioplasty following subarachnoid hemorrhage and were included. Patient and aneurysm characteristics in our study cohort are summarized in Table 1 .
Treatments
Among our 17 patients, a total of 82 vessel segments were treated with balloon angioplasty-35 of which were ACA segments. Angioplasty was performed on median post-bleed day 6 (range post-bleed day 3-20). Pre-angioplasty measurements revealed that 14% of ACA segments had mild angiographic vasospasm, 49% had moderate stenosis, and 37% had severe stenosis. Fortyone percent of patients underwent angioplasty of bilateral ACAs, and two patients required traversing the ACoA to access the contralateral ACA for angioplasty treatment. A summary of ACA balloon angioplasty treatments performed in this study is provided in Table 2 .
Outcomes
Following balloon angioplasty treatments, 94% of ACA segments had improved caliber, and the median relative increase in caliber was 63%. A clear neurological improvement was noted in 75% of awake patients. TCD within 24 hours of angioplasty showed improvement in 53% of patients. No patients experienced any complications during the balloon angioplasty treatments, but two patients developed asymptomatic ACA territory infarcts, despite angioplasty treatment. The median modified Rankin scale at the time of discharge was 3. Families of two patients elected to withdraw care. Mean clinical and angiographic follow-up was seven months (range 0.3-48 months). At follow-up, all patients were neurologically stable, and angiograms displayed patency of treated ACA segments. Two patients were lost to follow-up. Study cohort outcomes are outlined in Table 2 .
Discussion
Balloon angioplasty for vasospasm after SAH has been shown to be effective in cases refractory to spasmolytic injection and is known to improve clinical outcomes. [1] [2] [3] [4] Intracranial balloon angioplasty for vasospasm was first reported by Zubkov et al. in 1984. In their series of 33 patients, 105 vessels were successfully angioplastied, including A1 segments. Since then, multiple series have been published documenting the positive results of balloon angioplasty of the ICA, MCA, and posterior circulation vessels but not of the ACA segments. [5] [6] [7] [8] [9] [10] The few case series on angioplasty of the ACA consist of small patient cohorts. 1, 2, 5, 6, 14, 15 In fact, the literature on balloon angioplasty of the ACA describes this technique as challenging and nearly discourages neuroendovascular surgeons from performing the procedure. 5, 6, [13] [14] [15] [16] For example, Choi et al. reported that all of their angioplasty failures occurred due to the inability to navigate the balloon into the A1 segment. 5 Similarly, Terry et al. published only a 34% success rate of ACA balloon angioplasty, citing difficulty in advancing the balloon over the microwire in cases with severe vasospasm or unfavorable vessel angles. 6 Based on these results, current vasospasm treatment of the ACA typically entails spasmolytic infusions rather than balloon angioplasty, yielding less than optimal patient outcomes.
Anatomical challenges of the ACA segments stem from their small caliber and sharp angles. 1, 6, 17, 18 The average ACA diameter of 2.6 mm is smaller than the average MCA diameter of 3 mm. 1 In addition, vasospasm further narrows the vessels, and navigating the balloon across acute angles compounds the risks of vessel perforation, vessel dissection, and thromboembolic events. Several studies have subsequently focused on improving techniques to access the ACA segments. 17, 18 In this technique-assessment study, we demonstrate the safety and efficacy of balloon angioplasty of the ACA for vasospasm treatment after SAH. We present 17 consecutive patients at our institution who underwent successful balloon angioplasty of 35 ACA segments, 37% of which were A2 and A3 segments. To our knowledge, this is the largest series of successful ACA angioplasties reported in the literature. All patients displayed clinical and angiographic vasospasm. After failure of angiographic improvement of vasospasm was seen following intra-arterial verapamil infusion, patients underwent balloon angioplasty of the involved ACA segments. Nearly all segments improved in caliber, and 75% of examinable patients had a better neurological exam following angioplasty. It is also important to note that simultaneous treatment of ACA segments with angioplasty of other intracranial segments and with intra-arterial infusion of verapamil may have contributed to the improved clinical outcomes.
In our series, we encountered no peri-procedural complications, including no vessel perforation, vessel dissection, thromboembolic events, device malfunctions, retroperitoneal hematomas, or groin hematomas. The two patients in our cohort who developed asymptomatic ACA territory infarcts unrelated to the angioplasty procedure possibly had delayed recurrent vasospasm, delayed cerebral ischemia associated with SAH, or a period of hypotension. At a mean follow-up of seven months, all patients were neurologically stable, and angiograms displayed patency of all treated ACA segments.
Factors that favor successful ACA balloon angioplasty include minimal vessel angulation, distal vessel size that may accommodate the balloon, and a balloon design that can easily navigate through the ACA segments. Presence of an ACoA that can be traversed should also be recognized, since it can be used to approach contralateral stenotic segments if the contralateral A1 is either hypoplastic or too narrow to access. Additionally, careful measures can be taken to avert major complications related to balloon angioplasty, such as adequate systemic heparinization. Moreover, our technique of performing angioplasty from proximal to distal vessel segments as well as infusing verapamil before and during angioplasty may help to mitigate the anatomical challenges of the ACA vessels. The fact that ACA balloon angioplasty is feasible and safe suggests that it should be considered in the management of patients with symptomatic vasospasm recalcitrant to vasodilation infusion therapy. Nonetheless, it is imperative to apply this technique to appropriately selected patients. More specifically, patients with delayed cerebral ischemia unrelated to vasospasm can have fluctuating neurological exams and may improve without balloon angioplasty. In the absence of randomized evidence, the efficacy of this treatment is debatable, but our study suggests that proximal and distal ACA segments can and should be angioplastied when indicated if an experienced neuroendovascular surgeon is available.
Conclusions
We present one of the largest series of patients who successfully underwent balloon angioplasty of ACA segments for the treatment of vasospasm, thereby demonstrating that balloon angioplasty of the ACA can be performed with safety and efficacy. Thus, angioplasty of the ACA should be considered to treat vasospasm in symptomatic patients recalcitrant to vasodilation infusion therapy.
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